HSS Extends Network to Aspen

NEW YORKAug. 14, 2018 /PRNewswire/ — HSS, the New York-based health system that includes Hospital for Special Surgery, is forming a strategic co-management partnership with Aspen Valley Hospital (AVH) and its OrthoAspen specialist group, to provide the world’s most advanced orthopedic care to Aspen community members and visitors. Following months of development, the relationship was endorsed by a vote on August 13 among the AVH Board of Directors.

Hospital for Special Surgery has been ranked the No. 1 orthopedic hospital in the nation for the past nine consecutive years by U.S. News & World Report ‘Best Hospitals’ (2018-19). AVH, Colorado’s only five-star rated critical access hospital by the Centers for Medicare and Medicaid Services, will adopt HSS best practices standards and leverage its orthopedic resources and capabilities. HSS will provide AVH with services including clinical knowledge transfer, medical staff development, professional education, research and academic programming, and practice quality enhancement.

“This partnership is a great example of our different approach to transforming healthcare,” said Louis A. Shapiro, president and CEO of HSS. “Innovative collaboration amongst two organizations committed to excellence in a focused specialty offers an alternative source of value to the trend of mass consolidation and commoditization in healthcare.”

“Embedding HSS’s knowledge, expertise, and best practices in AVH, enables world-class care to be more accessible and more individuals to live life to the fullest,” he added.

“We are thrilled to partner with Aspen Valley Hospital, an exceptional institution in its own right,” said HSS Surgeon-in-Chief and Medical Director Dr. Todd J. Albert. “Together we will provide an even higher standard of quality to a community with an especially strong appreciation for the value that will come from that.”

“This is a unique opportunity to advance the excellence of OrthoAspen and assure the most discerning consumers of world-class orthopedic care right here in Aspen,” said Dave Ressler, CEO, Aspen Valley Hospital. “This transformative partnership is very exciting for both AVH and HSS because it clearly demonstrates our shared commitment to delivering the best possible orthopedic outcomes.”

“It will also enable us to better control costs and deliver value to the Aspen community,” added Mr. Ressler.

Both nonprofit hospitals have long histories serving their respective communities – HSS was founded in 1863 and AVH has been serving Aspen for 127 years.


Founded in 1891, Aspen Valley Hospital (AVH) is one of the most sophisticated rural hospitals in the U.S. With twenty-five beds, AVH is designated as a critical access hospital and level III trauma center, meeting the needs of the Aspen and Roaring Fork Valley communities, plus thousands of visitors from around the world every year. Combining the warmth and friendliness of a small town with the technical expertise of a major medical center, AVH has been recognized with numerous awards, including a Five-Star Rating from the Centers for Medicare and Medicaid; “Hospital of Choice” award (based on Hospital Consumer Assessment of Healthcare Providers and Systems results); and a “Top 20 Best Practice in Financial Stability” designation from the National Rural Health Association for critical access hospitals in the U.S., among others. AVH offers a full range of services with board-certified specialists in 25 fields of medicine, with expanded expertise in orthopedics and sports medicine. For over 125 years, Aspen Valley Hospital has been working to deliver extraordinary healthcare in an environment of excellence, compassion and trust. Learn more at aspenhospital.org or 970-925-1120.


The OrthoAspen team of physicians is dedicated to improving and restoring the health of recreational and competitive athletes, adults, seniors and children. OrthoAspen has earned worldwide acclaim for its expertise in orthopedic care, providing the latest technologies and comprehensive services for its patients. Utilizing diagnostic imaging technology, minimally-invasive techniques, and the Mako surgical robot for total and partial joint replacements, OrthoAspen brings state-of-the-art orthopedic care to Aspen and surrounding communities. OrthoAspen’s research findings have been reported in major medical journals and at academic conferences throughout the world. Learn more at orthoaspen.org or 970-544-1289.

About HSS | Hospital for Special Surgery

HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the ninth consecutive year) and No. 3 in rheumatology by U.S. News & World Report (2018-2019). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New JerseyConnecticut and in the Long Island and Westchester County regions of New York State. In 2017 HSS provided care to 135,000 patients and performed more than 32,000 surgical procedures. People from all 50 U.S. states and 80 countries travelled to receive care at HSS. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The culture of innovation is accelerating at HSS as 130 new idea submissions were made to the Global Innovation Institute in 2017 (almost 3x the submissions in 2015). The HSS Education Institute is the world’s leading provider of education on the topic on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally.

SOURCE Hospital for Special Surgery

Related Links


Orthopedics & Joint Replacement at Mercy Offers Patients Robotic-Arm Assisted Total Knee Replacement with MAKOplasty System

Orthopedics & Joint Replacement at Mercy Medical Center now offers a new advanced minimally invasive surgical option for patients needing total knee replacement: MAKOplasty Total Knee Replacement Surgery using robotic technology.

According to Dr. Marc Hungerford, Chief of the Division of Orthopedics at Mercy, this knee replacement treatment option is designed to relieve the pain caused by joint degeneration due to osteoarthritis. With the new MAKOplasty system, Mercy can offer patients a personalized surgical experience tailored to their specific diagnosis and anatomy.

The process begins with a CT scan of the patient’s knee joint which is used to generate a 3D virtual model of the patient’s anatomy. This model is then uploaded on to the MAKOplasty system software and is used to create a pre-operative plan, specific to that patient.

Robotic technology improves accuracy, allows the surgeon to make adjustments for muscular and soft tissue alignment, and yields better outcomes for patients, Dr. Hungerford explained.

“This advanced technology transforms the way joint replacement surgery is performed, enabling surgeons to more accurately position a patient’s joint replacement. The result is a better, and longer-performing joint, as well as a faster recovery after surgery,” Dr. Hungerford said. “In addition, this state-of-the-art implant gives patients natural range of motion.”

The MAKOplasty robotic-arm is guided by the surgeon to remove diseased bone and cartilage and then inserts the knee replacement. During the procedure, the surgeon can make any necessary adjustments while guiding the robotic-arm.

Recent research indicates there will be at least 3.5 million total knee replacements in the United States by 2030, with the demand for knee replacements growing even faster than the demand for hip replacements.

Named a “Best National Hospital in Orthopedics” by U.S. News and World Report, the surgeons of Orthopedics & Joint Replacement at Mercy are trained in the use of the MAKOplasty system, and can perform both total and partial knee replacement surgery.

“Our physician team includes top rated orthopedic surgeons, offering innovative hip replacement and knee preservation, replacement and treatment options as well as other treatments for a wide variety of orthopedic and sports medicine related issues,” Dr. Hungerford said.

Founded in 1874 by the Sisters of Mercy, Mercy Medical Center is a university-affiliated Catholic hospital with a national reputation in orthopedics and women’s health. For more information, visit Mercy online at http://www.mdmercy.com, MDMercyMedia on Facebook and Twitter, or call 1-800-M.D.-Mercy.

Brigham Redd, M.D. is first surgeon in Idaho to offer OMNIBotics® Robotic-assisted Total Knee Replacement

RAYNHAM, Mass.Aug. 8, 2018 /PRNewswire/ — OMNIlife science, Inc. (“OMNI”), a privately-held, established medical technology company targeting the $15 billion global hip and knee replacement device market, announced today that Brigham Redd, M.D., of Liljenquist & Redd Orthopedic Surgery, is the first surgeon in Idaho to offer OMNIBotics, an advanced robotic-assisted treatment option for total knee replacement. This innovative total knee replacement solution is designed to relieve the pain caused by joint degeneration due to osteoarthritis. OMNIBotics is the global leader in robotic-assisted total knee replacement, with over 7 years of clinical use worldwide. This treatment option will be available for Dr. Redd’s patients at both Mountain View Hospital and Eastern Idaho Regional Medical Center in Idaho Falls, ID.

The OMNIBotics procedure utilizes advanced software and instrumentation to tailor each procedure to the patient’s unique anatomy in order to optimize implant fit and alignment. Patented OMNIBotics Bone Morphing™ technology eliminates the need for costly CT scans or MRIs and allows the surgeon to perform “virtual surgery” on a digital model before any bone is cut. A robotic cutting guide is then used by the surgeon when making the planned bone resections to ensure accuracy. The surgeon maintains control and decision-making regarding the total knee replacement while providing a customized, patient-specific surgery. OMNIBotics also allows for a less invasive surgical technique, compared to traditional knee replacement surgery, which may promote a quicker recovery.

“It’s been great to be able to check the accuracy of the surgery and make adjustments to perfect the angles and alignment of each step of surgery. This is so much more personalized and accurate than the traditional knee replacements done elsewhere,” said Dr. Redd. “It’s exciting to offer the most advanced technology to my patients and see them come back feeling even better than they do after a traditional knee replacement, and to be confident that their knee replacement will last even longer because of the precise and individualized alignment.”

ABOUT OMNIlife science™, Inc. (OMNI™)

OMNI is a privately held company with a proprietary robotic platform, OMNIBotics®, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and enhance a surgeon’s ability to help patients live active and pain-free lives. For more information about OMNI, please visit www.omnils.com.


Cindy Holloway, Director of Marketing Communications 

Phone: (508) 824-2444  


SOURCE OMNIlife science, Inc.

Related Links


Conformis announces election of Carrie Bienkowski to its Board of Directors

BILLERICA, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient’s unique anatomy, announced today that its Board of Directors elected Carrie Bienkowski to the Board effective July 31, 2018.  Ms. Bienkowski will serve as a class I director until the Conformis 2019 Annual Meeting of Stockholders.

“We welcome the addition of Carrie Bienkowski to our Board of Directors,” said Kenneth P. Fallon, III, Chairman of the Board of Directors of Conformis. “Her knowledge in consumer marketing and digital innovation will be a great asset for Conformis.” “Carrie’s experience is consistent with the opportunity we have to position the Conformis brand among today’s active and engaged patients that are seeking orthopedic treatment,” added Mark Augusti, Conformis’ President and Chief Executive Officer.

Ms. Bienkowski is a dynamic operational and strategic leader with over 20 years of experience working across e-commerce, retail, blue-chip fast-moving consumer goods and management consulting. She has a proven track record of delivering results in diverse industries and international markets and is skilled in executive level strategic business planning, new product development, customer experience strategy and brand management.

Ms. Bienkowski has served as Chief Marketing Officer of Peapod since 2014. Prior to joining Peapod, Ms. Bienkowski served as the Head of Buyer Experience for eBay’s Fashion vertical in the European markets. From 2002-2009, at C&E Advisory in London, Ms. Bienkowski counseled businesses and brands including L’Oreal, Sky Media, HSBC, Boots Pharmacy and Vodafone in sustainability strategies. Earlier in her career, Ms. Bienkowski spent nearly a decade at Procter & Gamble, where she served in various brand management roles.

Ms. Bienkowski received her degree in finance and business economics from the University of Notre Dame.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. Conformis offers a broad line of customized knee implants and customized pre-sterilized, single-use instruments delivered in a single package to the hospital. In clinical studies, Conformis iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover customized implants and customized patient-specific instrumentation for all major joints.
For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release about our future expectations, plans and prospects, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. You should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our estimates and expectations regarding our results of operations, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Investor contact
Oksana Bradley
(781) 374-5598

Conformis Announces the first 3D Total Hip Replacement Surgeries performed at JFK Medical Center in Florida

BILLERICA, Mass., Aug. 01, 2018 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS), a medical technology company that offers patient conforming joint replacement implants, today announced completion of the first two Conformis Hip System implants. The Conformis Hip System is the first ever 3D designed primary total hip replacement system. The first surgeries were performed by Gregory Martin, M.D., Joint Fellowship Trained Orthopedic Surgeon and founder of Personalized Orthopedics of the Palm Beaches, and took place at a leading HCA Facility, JFK Medical Center in Atlantis, Florida on July 31, 2018.

“Partnering with our expert surgeon design team and leveraging our extensive experience in automated 3D printing and additive manufacturing enabled us to bring a revolutionary new hip replacement system to market. Our 3D implant design process provides surgeons with interactive input and improves operational efficiencies compared to 2D templating. The design process produces specific individualized pre-navigated cutting guides and implants. A groundbreaking acetabular reaming system has also been developed,” said Mark Augusti, chief executive officer and president of Conformis. “With this launch, we expect to lead the way in innovative solutions for the $7B hip replacement market by providing surgeons with game-changing operative solutions to better serve them and their patients both in hospitals and ambulatory surgical settings.”

Similar to the design process for the Conformis Knee technologies, the Conformis Hip System uses proprietary advanced imaging and design software, to design, manufacture and deliver the suite of FDA-cleared patient conforming Knee and Hip replacement implants. After each patient’s CT scan is converted into a 3-dimensional computer model, the unique measurements of each patient’s anatomy are transformed into a comprehensive, individualized, pre-operative surgical plan that is delivered to the surgeon well in advance of the operation. Surgeons are able to collaborate with Conformis during the planning process in order to design the optimal Hip System for each patient based on surgeon preferences.

“The Conformis Hip System is designed to address many of the short comings of primary hip replacement today. For the first time, orthopedic surgeons have a fully-guided system designed to address the wide variations in anatomy presented across our cases,” said Dr. Martin M.D*, a member of the surgeon design team. “The Conformis system builds upon traditional methods for hip replacement surgery with proven materials and components which, today, are offered in only limited standard configurations. Due to the accuracy of the personalized pre-operative surgical plan, the 3D printed patient conforming cutting guides and hip implant components, my hope is that with the new Conformis Hip system, surgeons will be able to improve both patient outcomes and operational efficiencies.”

Each component of the Conformis Hip System is pre-navigated to fit the patient, with certain components designed specifically for that patient. The Conformis Hip System is delivered directly to the hospital or surgery center in a single patient-labeled kit, eliminating the need for excess inventory. Patient conforming, single-use, 3D printed cutting guides are also included, limiting the need for the vast amount of reusable instruments required for a standard off-the-shelf total hip replacement.

The first two Conformis Hip System surgeries were conducted as part of a limited launch. Timing for a complete commercial launch is expected to be announced in 2019.

The global hip joint reconstruction market is projected at over $7B, and about 400,000 total hip replacements are performed in the United States each year.

*Gregory Martin, MD is a consultant to Conformis, Inc.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are designed and manufactured to fit and conform to each patient’s unique anatomy. Conformis offers a broad line of patient conforming total and partial knee systems and a hip system that include sterilized single-use instruments delivered in a single package to the hospital. Conformis owns or exclusively in-licenses over 400 issued patents and pending patent applications that cover patient-specific implants and instrumentation for all major joints. In clinical studies, Conformis iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release about our future expectations, plans and prospects, including statements about the anticipated timing of our product launches, and our financial position and results, total revenue, product revenue, gross margin, operations, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. You should not place undue reliance on our forward-looking statements. Actual results could differ materially from the expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Media Contact:

Kelly Wakelee



Investor Contact:

Oksana Bradley


(781) 374-5598

A photo accompanying this announcement is available at: http://www.globenewswire.com/NewsRoom/AttachmentNg/e52cfbc4-fc9b-4c4d-b337-1990354e34a7

The photo is also available via AP PhotoExpress.

Source: Conformis, Inc.

This article appears in: News Headlines

Referenced Stocks: CFMS


CloudMedx Working With UCSF to Create AI Models for Improving Patient Outcomes After Joint Replacement Surgery

PALO ALTO, Calif., July 30, 2018 (GLOBE NEWSWIRE) — CloudMedx, a healthcare artificial intelligence (AI) company based in Palo Alto, Calif., announced today a research collaboration with the UCSF Department of Orthopaedic Surgery to study how patient-generated health care data collected from consumer-grade wearable sensors may predict clinical outcomes following hip and knee replacement surgery.

By looking at structured and unstructured data from patient medical records, as well as from wearable devices, the UCSF research team, advised by the National Science Foundation’s Center for Disruptive Musculoskeletal Innovations, aims to create a new class of algorithms that can predict a patient’s individual outcome and recovery following surgery.

“We want to combine patient-reported outcomes, data from electronic medical records and sensor data to predict how patients will recover following joint replacement surgery,” said project leader Stefano Bini, MD, UCSF Health orthopedic surgeon and professor of orthopedic surgery at UCSF. “To give us a perspective on how patients are doing with predictive analytics, we partnered with CloudMedx to handle the large data sets that will be needed.”

According to Dr Bini, the current gold standard for patient evaluations are validated patient reported outcome surveys, which are obtained prior to surgery and at one year following surgery, when the maximum improvement is deemed to have been reached. However, data points gathered in the interim have not been validated and are generally discouraged.

“The hope is that we can overcome these shortcomings by gathering data from sensors that can objectively measure in real time steps, cadence, heart rate and other variables with a patient’s clinical record to accurately predict their outcomes,” Dr. Bini said. “There currently is a huge cache of unstructured information in the medical records in the form of physician notes, nurse progress notes, discharge summaries, radiology notes and patient-reported outcomes that is being overlooked due to lack of resources. By using CloudMedx’s robust AI to read clinical notes using machine-assisted natural language processing, we aim to surface insights in real time to improve patient outcomes.”

According to Dr Bini, “Engaging Cloudmedx as our analytics platform allowed us to derive relationships and incredible insights using state of the art ML algorithms. Rather than the standard and rather useless calculation of relative Hazard and Risk Ratios of one outcome versus another when looking at one variable and adjusting for all others (“useless” because the resulting data is incredibly hard to apply in clinical practice where patients present with multiple variables many of which like gender and age are not at all variable), the algorithm was able to clearly identify cohorts (clusters) of people whose variables (features) were more likely to be associated with a given outcome (PRO) and take any specific candidate and place them in a risk cluster. This is phenomenal and way more practical.”

Very preliminary data was presented this spring at the Orthopedic Research Society. Early signals have demonstrated what kind of data is predictive of what kind of outcome and that it may predict 6-week PROs with a high degree of accuracy in a given individual as early as 2 weeks following surgery.

About CloudMedx
CloudMedx is a clinical artificial intelligence platform that provides real time clinical insights to the healthcare industry with the goal of improving clinical and operational outcomes. The company uses evidence-based algorithms, machine learning and natural language to sift through both unstructured data as well as structured data to help providers and health systems improve care delivery, reduce costs, and optimize their workflows. For more information, visit www.cloudmedxhealth.com.

UC Disclaimer
The information stated above was prepared by CloudMedx to report on research conducted on its product and reflects solely the opinion of CloudMedx. Nothing in this statement shall be construed to imply any support or endorsement of CloudMedx, or any of its products, by The Regents of the University of California, its officers, agents and employees.

Sahar Arshad
CloudMedx Inc

JOURNEY™ II BCS Knee System demonstrates improved patient outcomes and lower healthcare costs

LONDONJuly 25, 2018 /PRNewswire/ — Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announced positive clinical results concerning its JOURNEY™ II Bi-Cruciate Stabilized (BCS) knees. These results suggest JOURNEY II BCS is associated with significant healthcare economic benefits in patients implanted with this device compared to other knee systems.

In a retrospective cohort study from the Premier Perspective Database1, JOURNEY II BCS patients exhibited lower mean hospital stays and overall reduced mean costs when compared to other knee patients.  When comparing 1,692 JOURNEY II BCS patients to the same number of other comparable knee patients, data revealed JOURNEY II BCS patients were:

  • 51% less likely to be readmitted to the hospital within 30 days;
  • 35% more likely to be discharged to their home; and
  • 41% less likely to be discharged to a skilled nursing facility for further care.

The results also showed patients with JOURNEY II BCS experienced statistically significantly reduced length of stay and reduced hospital costs, equivalent to approximately 10% in savings to the overall procedure cost ($16,187 vs. $17,877).

Andy Weymann MD, Chief Medical Officer of Smith & Nephew, commented: “To have a knee system that improves patient outcomes while reducing healthcare costs is a tremendous feat for Smith & Nephew.  When we introduced the JOURNEY II Knee System, we wanted to build upon our 150+ years of supporting healthcare professionals and patients in a way that addressed the market where patient outcome measures go beyond implant survivorship.  We know hospitals and healthcare professionals have a wide choice in knee implants and this new retrospective analysis supports our view that JOURNEY II BCS is the leading knee platform available in today’s market.”

The Premier Perspective Database study is not the only recent evidence reporting improved patient outcomes with the JOURNEY II BCS Knee System. In another multi-center study published in Techniques in Orthopaedics, JOURNEY II BCS patients demonstrated a smoother recovery, improved function and increased patient satisfaction.2-6 Specifically, study patients implanted with JOURNEY II BCS had 23 degrees more flexion than patients implanted with another comparable knee system along with significantly improved mean knee society scores (89 vs 81; p<0.001) at 1 year follow-up.2

“Every knee product we manufacture is designed to improve patient outcomes while decreasing hospital costs. It is rewarding to see JOURNEY II BCS patients demonstrating a smoother recovery1-2 and higher patient satisfaction than what we have seen in the past. These outcomes illustrate the value that Smith & Nephew constantly strives to provide to our healthcare system,” Brad Cannon, Chief Marketing Officer.

The JOURNEY II BCS is a member of the JOURNEY II Total Knee Arthroplasty (TKA) system, which also includes JOURNEY II Cruciate Retaining (CR) and the recently launched bi-cruciate retaining JOURNEY II XR.

About Smith & Nephew 

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic ReconstructionAdvanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.comfollow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

Forward-looking Statements 

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include:

economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.

™Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office.

  1. Mayman DJ, Patel AR, Carroll KM. Hospital Related Clinical and Economic Outcomes of a Bicruciate Knee System in Total Knee Arthroplasty Patients.Poster presented at: ISPOR Symposium; May 19-23, 2018Baltimore, Maryland, USA.
  2. Nodzo, SR; Carroll KM, Mayman DJ. The Bicruciate Substituting Knee Design and Initial Experience. Tech Orthop. 2018;33:37-41.
  3. Scott CE, Howie CR, MacDonald D, Biant LC; Predicting dissatisfaction following total knee replacement: a prospective study of 1217 patients. J Bone Joint Surg Br. 2010 Sep;92(9)
  4. J Orthop. 2017 Jan 7;14(1):201-206. doi: 10.1016/j.jor.2016.12.005. eCollection 2017. Bi-cruciate substituting total knee arthroplasty improved medio-lateral instability in mid-flexion range
  5. In Vivo Kinematic Comparison of a Bicruciate Stabilized Total Knee Arthroplasty and the Normal Knee Using Fluoroscopy Trevor F. Grieco, MS a, *, Adrija Sharma, PhD a, Garett M. Dessinger, BS a, Harold E. Cates, MD b, Richard D. Komistek, PhD. The Journal of Arthroplasty, September 2017
  6. A comparison of Rolback Ratio between Bicruciate Substituting Total Knee Arthroplasty and Oxford Unicompartmental Knee Arthroplasty. DOI: 10.1055/s-0037-1604445. ISSN 1538-8506. The Journal of Knee Surgery. Takanori Iriuchishima, Keinosuke Ryu

SOURCE Smith & Nephew

Related Links


Using Patient-Specific 3D Printed Surgical Guides for Total Knee Replacement

by  | Jul 13, 2018 | 3D PrintingMedical 3D Printing

While surgery has always, ultimately, been about the patient, it hasn’t always been patient-centered. Historically, patients have not had an easy time of understanding exactly what their surgery entails and have often been treated as if they were ancillary to the surgical problem presented. This can’t all be blamed on uncaring medical staff, as most people involved in medicine do care and care profoundly. Instead, it has largely been a result of resources and standing custom. Surgical procedures are complicated and difficult to understand, hence the reason why experts are the ones who address them, and the pressure and stress involved in going into a procedure largely blind has made it difficult for surgeons to relax and broaden their focus to include the patient beyond the problem.

3D technology is making great contributions to medicine, from aiding in research to assisting in the preparation of students to practice medicine to producing the tools necessary to perform better operations. It is being integrated into the surgical theater and changing the face of surgery as we know it. One of the ways it is doing this is through the provision of a greatly improved ability to plan for the procedure. 3D technology not only allows the medical team a sneak preview, 3D printing can create models of the particular areas to be addressed and allow surgeons to study them in advance. This helps minimize surprises and therefore reduces the stress on both the patient and the medical staff.

The staff at Orthoparc in the Netherlands has figured out another way to help create and deliver the best in patient centered care. Using 3D technology, they have developed a method of patient-centered total knee replacement that allows a patient to walk in, in the morning, and walk out that same day. Such a possibility requires a highly interconnected team of specialists working together to ensure that not only does the patient get the knee replacement they need, but their psychological, nutritional, and whole health needs are met as well.

One component of this is the integration of 3D printed, patient-specific surgical guides that take the uncertainty out of the procedure itself. These surgical guides are produced using data gathered about an individual patient’s knee and are fabricated in-house on a 3D printer. When placed upon the patient during surgery, they guide the surgeon to exactly where cuts need to be made in relationship to where the knee is resting. Dr. Saskia Boekhorst is an orthopedic surgeon at Orthoparc, and she described the impact these guides have had in her experience.




Local Orthopedic Surgeon, Ritesh Shah, MD, Receives Innovation Trailblazer Award for Adoption of New Navigation System for Hip Replacement Surgery

MORTON GROVE, ILJuly 16, 2018 /PRNewswire/ – Orthopedic surgeon, Ritesh Shah, MD, was honored with the IJS Innovation Trailblazer Award of Excellence acknowledging early adoption of intellijoint HIP® into his practice at Illinois Bone & Joint Institute and in an Ambulatory Surgery Center (ASC) setting at Illinois Sports Medicine & Orthopedic Surgery Center (ISMOSC) in Morton Grove.

intellijoint HIP is a highly accurate 3D mini-optical navigation system used to assist in proper size selection and positioning of artificial implants during a hip replacement. Dr. Shah is the first orthopedic surgeon in Illinois to offer this new technology in an outpatient or ASC setting.

“Many of my patients come to me in pain looking to regain their former mobility, but are worried about the short- and long-term risks associated with total hip replacements,” explained Dr. Shah. “By utilizing the quantitative measurements that intellijoint HIP provides intraoperatively, I am able to ensure the implants have been positioned accurately resulting in a significant decrease of associated risks. Patients are back to their active lifestyles in just days, confident in their surgical outcomes.”

A total hip replacement is typically an effective surgery that can reduce hip pain and restore mobility. The risks of this procedure can include leg length discrepancy, dislocation, joint instability, reduced muscle strength, reduced hip range of motion, and long-term pain. intellijoint HIP addresses these risks by providing accurate, intraoperative measurements for cup position, leg length, and offset to assist the surgeon in placing implants in a location that best matches the patient’s native anatomy.

“Intellijoint Surgical is proud to present the Innovation Trailblazer Award to Dr. Shah today,” said Armen Bakirtzian, CEO, Intellijoint Surgical. “We want to acknowledge not only his adoption of intellijoint HIP, but his overall commitment to better surgical outcomes through exploring new advances in the field — both in technique and in technology.”

About Dr. Ritesh Shah:

Dr. Shah is a nationally recognized, board-certified, fellowship-trained orthopedic surgeon who specializes in hip and knee replacements in the outpatient setting. His mission is to return patients to their active lifestyle as quickly and as safely as possible. He travels and teaches colleagues worldwide about new advances in same day hip and knee replacement, hip arthroscopy, joint revision surgery, and the Rapid Recovery Reality approach to orthopedic care.

About Intellijoint Surgical:

Intellijoint Surgical® develops and commercializes surgical navigation solutions. Intellijoint’s flagship product, intellijoint HIP® provides surgeons with real-time, intraoperative measurements to ensure accurate positioning of orthopedic implants during Total Hip Arthroplasty. Intellijoint is committed to improving patients’ lives by providing every surgeon with effective, easy-to-use technology.

SOURCE Intellijoint Surgical Inc.

Related Links


Stryker Brings The Mobility Zone® To Constellation SENIOR PLAYERS Championship

MAHWAH, N.J.July 11, 2018 /PRNewswire/ — Stryker announced today plans to activate The Mobility Zone® at the Constellation SENIOR PLAYERS Championship taking place in Highland Park, Illinois at Exmoor Country Club. Stryker will continue its commitment to educating golf fans about joint health through the interactive destination, where tournament-goers can speak with orthopaedic surgeons about potential treatment options and Stryker’s Mako Technology. In addition, Stryker will demonstrate its support for veterans during a ceremony in the Patriots’ Outpost on Friday, where Stuart Simpson, President, Stryker’s Joint Replacement Division, will present a donation to K9s For Warriors.

Marking the company’s nineteenth sponsored dog with the organization since 2015, Stryker’s donation Friday will allow K9s For Warriors to find, train and match a service dog with a veteran suffering from Post-Traumatic Stress Disability, traumatic brain injury or other military trauma as a result of military service post 9/11, giving the veteran a new leash on life.

“K9s For Warriors is a fantastic organization, which Stryker is very proud to have a relationship with,” said Simpson. “I’m honored to present this donation on behalf of Stryker. We are extremely passionate about supporting veterans and sponsoring a service dog that will provide them the support they need is a truly rewarding feeling.”

The ceremony, which begins at 11 a.m., will also include Marine veteran, and K9s For Warriors graduate, Tyler Leonard. Leonard will share his personal story of living with PTSD and the incredible support his service dog, Bella, has given him.

During the tournament, fans are invited to visit The Mobility Zone to learn about joint health and Mako Robotic-Arm Assisted Surgery –the latest advancement in joint replacement technology. A destination designed to engage and educate fans, The Mobility Zone offers a unique opportunity for tournament-goers to speak with local orthopaedic surgeons.

A premier feature of The Mobility Zone, the Accuracy Challenge allows fans to gain a better understanding of joint replacement and Stryker’s Mako Technology. This interactive experience challenges fans to remove arthritic bones from a life-size model named Art H. Ritis and replace them with Stryker implants.

Stryker will also be present throughout the course with its 1.7-mile health walk featuring interactive signs designed to educate fans about joint health and challenge them with golf trivia.

For additional information on the Stryker Accuracy Challenge as well as K9s For Warriors involvement, please visit: patients.stryker.com.                                                                                 

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at stryker.com.


By showcasing golf’s greatest players, the PGA TOUR engages, inspires and positively impacts our fans, partners and communities worldwide.

The PGA TOUR co-sanctions more than 130 tournaments on the PGA TOUR, PGA TOUR Champions, Web.com Tour, PGA TOUR Latinoamérica, Mackenzie Tour-PGA TOUR Canada and PGA TOUR Series-China. Members on the PGA TOUR represent the world’s best players, hailing from 27 countries (88 members are from outside the United States). Worldwide, PGA TOUR tournaments are broadcast to more than 1 billion households in 226 countries and territories in 23 languages. Virtually all tournaments are organized as non-profit organizations to maximize charitable giving. In 2017, tournaments across all Tours generated a record of more than $180 million for local and national charitable organizations, bringing the all-time total to $2.65 billion.

The PGA TOUR’s web site is PGATOUR.COM, the No. 1 site in golf, and the organization is headquartered in Ponte Vedra Beach, Florida.

SOURCE Stryker

Related Links